Futura Medical plc
("Futura" or the "Company")
Directors'/PDMR Dealing and Grant of Options
10 October 2023
Futura Medical plc (AIM: FUM) (the "Company"), the pharmaceutical company developing innovative sexual health products, announces a grant of 10,590,675 options over Ordinary Shares ("Options") to employees and Directors.
Grant of Options
The Company has granted a total of 10,590,675 Options of which 4,084,681 have been awarded to Directors as detailed below.
All Options have been granted under existing schemes, granting was subject to the achievement of performance-based milestones and will vest equally over 3 years to October 2026 with 25% of the Options granted with immediate vesting. The main ongoing vesting condition is that the individual remains an employee or Director at the time of vesting.
| Director | Number of Options granted | Exercise price | Total number of Options held following grant |
| James Barder | 1,450,211 | 0.2p | 3,615,927 |
| Angela Hildreth | 1,267,742 | 0.2p | 3,040,082 |
| Ken James | 1,366,728 | 0.2p | 3,375,953 |
Full details of the Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.Futuramedical.com
Nomad and Sole Advisor
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin/ Jonathan Edwards/ Zoe Bolt/ Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted two Phase 3 studies using MED3000 in ED; FM57 study which enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura to be granted US marketing authorisation. Both studies demonstrated that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favourable benefit versus risk profile ideally suited for an 'Over the Counter' classification.
Eroxon® is FDA approved in the US, CE marked in?Europe?and UKCA marked in the?UK?as a clinically proven topical treatment for adult men with erectile dysfunction under the brand Eroxon® with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is the agreed brand name in certain regions such as the EU whereas MED3000 continues to be the internal code name used by the Company and also in reference to countries where regulatory approval or commercial distribution agreements have not yet been achieved. www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a)
| Name | James Barder | ||||
| 2 | Reason for the notification | |||||
| a)
| Position/status
| Director/ PDMR | ||||
| b)
| Initial notification /Amendment
| Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a)
| Name
| Futura Medical plc | ||||
| b)
| LEI
| 21380053QLT46UNV2303 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument
Identification code
|
Options over Ordinary shares of 0.2p each
GB0033278473 | ||||
| b)
| Nature of the transaction
| Grant of Options over Ordinary Shares | ||||
| c)
| Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
- Aggregated volume
- Price
|
Not applicable
| ||||
| e)
| Date of the transaction
| 9 October 2023 | ||||
| f)
| Place of the transaction
| Outside of trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a)
| Name | Angela Hildreth | ||||
| 2 | Reason for the notification | |||||
| a)
| Position/status
| Director/ PDMR | ||||
| b)
| Initial notification /Amendment
| Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a)
| Name
| Futura Medical plc | ||||
| b)
| LEI
| 21380053QLT46UNV2303 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument
Identification code
|
Options over Ordinary shares of 0.2p each
GB0033278473 | ||||
| b)
| Nature of the transaction
| Grant of Options over Ordinary Shares | ||||
| c)
| Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
- Aggregated volume
- Price
|
Not applicable
| ||||
| e)
| Date of the transaction
| 9 October 2023 | ||||
| f)
| Place of the transaction
| Outside of trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a)
| Name | Ken James | ||||
| 2 | Reason for the notification | |||||
| a)
| Position/status
| Director/ PDMR | ||||
| b)
| Initial notification /Amendment
| Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a)
| Name
| Futura Medical plc | ||||
| b)
| LEI
| 21380053QLT46UNV2303 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument
Identification code
|
Options over Ordinary shares of 0.2p each
GB0033278473 | ||||
| b)
| Nature of the transaction
| Grant of Options over Ordinary Shares | ||||
| c)
| Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
- Aggregated volume
- Price
|
Not applicable
| ||||
| e)
| Date of the transaction
| 9 October 2023 | ||||
| f)
| Place of the transaction
| Outside of trading venue | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.